Introduction
Follicular lymphoma (FL) is the most frequent indolent lymphoma and is considered virtually incurable with high response rates to therapy but frequent relapses [1] .
Progression to aggressive diffuse large B-cell lymphoma (DLBCL) occurs in about 35% of cases, an event associated with poor outcome [2] . Malignant FL B cells express germinal center (GC) B-cell markers such as BCL6 and CD10, have somatically mutated immunoglobulin variable genes with ongoing intraclonal diversification, and display a gene expression profile of centrocytes, indicating that FL results from the malignant transformation of GC-derived B cells [3] . The genetic hallmark of FL is the t(14;18) translocation associated with an overexpression of the anti-apoptotic protein BCL2, actively repressed in normal GC B cells. However, this founder genetic event is detected at a low frequency in most healthy individuals within peripheral blood IgM memory B cells, the so-called FL-like cells (FLLC) [4] , suggesting that additional driver genetic events are required to complete cell transformation. Accordingly, genome-wide profiling has recently shed new lights on the mutational landscape in FL and delineated a hierarchical model of successive genetic events supporting FL tumorigenesis [1, 5] .
Besides the failure of primary FL cells to survive and grow autonomously in vitro, the major role of the microenvironment in FL development and evolution has been highlighted by several seminal observations. First, like their normal counterpart, malignant FL B cells are found admixed with lymphoid stromal cells, macrophages, and follicular helper CD4 pos T cells (T FH ) in GC-like follicles within invaded lymph nodes (LN) [6] . In addition, bone marrow (BM) infiltration found in up to 70% of patients at diagnosis is characterized by an ectopic differentiation of lymphoid-like stromal cells [7] and local enrichment in CD4 pos T cells [8] suggesting a critical dependence of malignant B cells to this specific supportive cell niche. Despite these similarities, some differences in cell composition and organization exist between LN and BM niches [8, 9] . In agreement, different subclones could be detected within BM and LN, and BM FL cells are characterized by a lower cytological grade and proliferation [9] [10] [11] . These data support the hypothesis that trafficking in various specific microenvironments could contribute to FL clonal selection and molecular heterogeneity [12] . Second, several highly frequent genetic alterations are not oncogenic per se but favor the crosstalk of FL cells with neighboring cells. Among them, mutations in TNFRSF14/HVEM affecting its expression or binding to the inhibitory receptor BTLA could contribute to the maintenance and supportive activity of BTLA hi FL-infiltrating T FH [13, 14] . Moreover, more than 90% of FL cases display unusual sites for N-linked glycosylation within their immunoglobulin variable regions introduced during the somatic hypermutation process (SHM) [15] . Added glycans contain oligomannoses that might interact with C-type lectins expressed by myeloid cells in the microenvironment, allowing FL cells to receive antigen-independent but cell contact-dependent survival signals through their BCR [16] . Finally, several studies based on expression profiling and immunohistochemistry have proposed a panel of prognostic biomarkers reflecting the number, activation, and/or spatial organization of infiltrating immune cells, further emphasizing the central role of FL microenvironment [17] . In the landmark study performed on whole tumor biopsies, the clinical outcome of FL patients was primarily predicted by molecular features of non-malignant cells and not by specific genetic characteristics of tumor B cells [18] .
However, these studies led to highly contradictory results, in part due to treatment heterogeneity, and remained essentially descriptive without transposition of the data into more functional and mechanistic approaches. 
Microenvironment can inhibit FL cell growth
FL has long been considered as particularly immune responsive based on reports of spontaneous regressions, high response rates to monoclonal antibodies (mAb) associated with a long-lasting vaccinal effect, and good biological responses to vaccination using tumor-specific idiotype or immunogenic neoplastic cells [19] [20] [21] [22] .
Several immune cell subsets could contribute to this anti-tumor activity and provide useful biomarkers and potential therapeutic targets. [25] . T cells at the follicular border form lytic synapse-like structures with FL B cells, suggesting a tonic control of malignant cell trafficking and FL progression.
Cytotoxic lymphoid cells
However, a global CD8 pos T-cell exhaustion as well as dysfunctional synapses with FL B cells have been reported in biopsy specimens [26, 27] . In addition, intratumoral regulatory T cells (Treg) have been shown to inhibit in vitro degranulation and cytotoxic activity of infiltrating CD8 pos T cells exposed to lymphoma B cells [28] .
Beside antigen-driven cytotoxicity of CD8 pos T cells, innate anti-tumor cytotoxicity involved essentially NK cells and γδ T lymphocytes ( Figure 1 ). Our knowledge of in situ NK cells in FL is limited, and the low frequency of CD56 pos cells on malignant tissue sections has not been associated with the progression of the disease [29] .
However, we could hypothesize an induction of NK-DC crosstalk by therapeutic mAb, which could trigger tumor antigen-specific T cell immunity [30] . 
Myeloid cells
Tumor-associated macrophages (TAM) exhibit a dual role in FL pathogenesis, as underlined by the opposite predictive value of a high TAM content, depending on treatment schedule. In fact, high numbers of CD68 pos or CD163 pos TAM are associated with adverse outcome in FL patients treated with conventional chemotherapy, whereas this prognosis value is abrogated or even inversed when Rituximab is combined with chemotherapy [37] [38] [39] . These data suggest that FL TAM could favor tumor progression but also contribute to the clinical efficacy of antibodybased anti-lymphoma drugs ( Figure 2) . Accordingly, B cell depletion with anti-CD20 mAb in mouse models prominently depends on macrophages, and more specifically on their expression of activating FcγR [40] . In addition, for rituximab-mediated tumor clearance in human, antibody-dependent cellular phagocytosis (ADCP) mediated by macrophages probably plays a key role beside that of NK-mediated ADCC [41] . In particular, Rituximab and Ofatumumab show high direct ADCP capacities in vitro and elicit TNF-α release by macrophages, which could indirectly contribute to NK cell activation [42] . Interestingly, alternatively activated M2 macrophages were shown to display in vitro a greater phagocytic capacity towards Rituximab-opsonized B cells from chronic lymphocytic leukemia (CLL), when compared to M1 proinflammatory macrophages [43] . This was associated with a differential regulation of FcγR expression by polarizing cytokines. In agreement, several reports demonstrate that IL-4 decreases expression of CD64/FcγRIa whereas IL-10 up-regulates all classes of FcγR and favors CD32a/FcγRIIa-mediated phagocytosis [44] . FL TAM display a Altogether, TAM appear as a highly plastic cell subset involved in antitumor immunity, in particular through FcγR-related ADCP, a process actively inhibited by CD47-expressing malignant B cells.
Relevance for the design of new therapies
The demonstration that several immune cell subsets could efficiently trigger FL B-cell death is difficult to reconcile with the general lack of clinical response following classical antigen-specific immunotherapy strategies. In particular, despite promising proof-of-principle studies, the results of phase III randomized trials examining the clinical impact of idiotypic vaccination in FL were disappointing [21] . restoring Rho GTPase activity [50] . The relevance of this mechanism for the clinical activity of lenalidomide in FL remains to be evaluated.
Another important research field is the engineering of modified antibodies with optimized effector properties [51] . GA101 afucosylated anti-CD20 mAb is currently under clinical evaluation in FL and is supposed to mediate greater NK-cell ADCC through a higher affinity for CD16/FcRγIIIA that abrogates the negative impact of the unfavorable FcRγIIIA polymorphism [42] . However, GA101 recently demonstrated inferior ADCP compared with rituximab suggesting that new Fc modifications are required to improve specific binding to CD32a and enhance phagocytosis [52] .
Besides targeting directly tumor cells, a new generation of antibodies has been designed to stimulate immune cells in the microenvironment (reviewed in [53] ).
Among them, agonistic antibodies targeting the inducible co-stimulatory molecule CD137 could favor ADCC and T-cell activation and enhance the antilymphoma activity of anti-CD20 mAb [54] . Similarly, antibodies blocking KIR, the NK inhibitory receptor family, could be useful despite their systemic activation of resting NK cells [55] . Finally, promising immunological and clinical results have been obtained using combination of rituximab, BrHPP, and IL-2 in relapsed FL patients, suggesting that γδ T cells could be activated in vivo and trigger direct cytotoxic activity as well as ADCC owing to their inducible CD16 expression [56] . Targeting immune cells to increase their effector functions should thus be considered as a promising therapeutic strategy in FL, in particular with the aim of optimizing mAb-driven cytotoxicity.
Microenvironment can favor FL cell growth
Besides its potential role in tumor eradication, FL microenvironment revealed individual tumor supportive activity of each cell subset, including stromal cells, T FH , or TAM, on malignant B-cell recruitment, survival, proliferation, and drug resistance. In addition, the FL cell niche should be envisioned as a dynamic network of cell interactions where the various cell compartments also contribute to migration, expansion, activation, and polarization of each other.
Stromal cells
Cancer-associated fibroblasts (CAF) are phenotypically and functionally different from their normal counterpart and play a key role in tumor development and progression in various cancer models [57] . In FL, LN and BM CAF essentially display some features of lymphoid stromal cells, a heterogeneous cell compartment organized as three specialized cell niches within normal secondary lymphoid organs Interestingly, MSC isolated from spontaneous lymphomas in mouse also overexpress CCR2 ligands and recruit more macrophages than BM-MSC [79] . In addition, IFN-γ primes human and mice FRC to produce the immunosuppressive enzymes indoleamine-2,3 dioxygenase (IDO) and nitric oxide synthase 2 (iNOS), respectively [80, 81] . Since IFN-γ is upregulated within FL microenvironment [80] , such primed FRC could thereafter inhibit T-cell proliferation and contribute to tumor immune escape.
In conclusion, stromal cells play a central role in FL pathogenesis through both a direct tumor B-cell supportive activity and an indirect effect on the orchestration of FL cell niche.
CD4 pos T cells
Genes related to CD4 pos T cells represent a prominent part of the FL specific prognostic signature at diagnosis emphasizing the pivotal role of this subset ( that T FR are the more relevant Treg subset for FL biology [91] . These cells share phenotypic characteristics with T FH , and express a higher level of BCL6, the master regulator of T FH differentiation pathway, than classical Treg [85] . T FR also strongly express the co-stimulatory molecule ICOS, as reported for a subset of Treg with strong suppressive functions and able to induce IL-4-secreting T cells [92] .
Suppressive T FR have also been described in mice. They control the GC reaction by limiting T FH number and inhibiting the selection of non-cognate B cells [93] .
Nevertheless, the targets of the specific FL-T FR subset are currently unknown. 
Myeloid cells
Although several studies have proposed TAM number as a prognostic marker, knowledge of their direct role in B-cell growth and how they cooperate with neighboring infiltrating T cells and stromal cells is still rudimentary (Figure 2 ). BAFF is a well-known myeloid-derived B-cell growth factor. Even if BAFF expression is not increased in FL patients [94] , a polymorphism in TNFSF13B/BAFF was associated with an increased risk of developing FL, whereas a germline mutation in TNFRSF13C/BAFF-R was specifically detected in 10% of FL patients in association with a stronger BAFF-induced signaling [95, 96] . Another potential TAM-mediated pathway in FL is BCR signaling. In fact, whereas a recent study suggests that BCR from a subset of FL patients recognize self-antigens potentially retained on the surface of FDC [97] , the majority of FL B cells express mannosylated BCR able to interact with C-type lectins DC-SIGN (CD209) and Mannose Receptor (CD206)
independently of antigens [15, 16] . CD209 and CD206 are known to be upregulated on M2 macrophages and on TAM in solid tumors [98] , a situation mirrored in FL by the overexpression of IL-4 by T FH [45] . FL-T FH also overexpress CD40L that both increases IL-15Rα expression on myeloid cells [99] and confers IL-15 sensitivity to B cells through induction of STAT5 expression and activation [70] . In agreement, FL-TAM overexpress IL15 compared to tonsil macrophages and FL B cells overexpress STAT5A compared to normal GC B cells. Interestingly, IFN-γ, which is also upregulated in FL microenvironment [80] , was shown to increase the migration of macrophages in response to CCL2 through an upregulation of STAT1 expression [100] . Such activation loop should be important for the recruitment of macrophages by CCL2 hi FL stromal cells and the presence of STAT1 pos CD68 pos macrophages in the vicinity of FL B cells was associated with unfavorable outcome [101] . Finally FL-TAM could contribute to local immune escape through the release of immunosuppressive molecules like IL4I1 [102] but also to angiogenesis. Accordingly, increased angiogenic sprouting correlates both with elevated numbers of CD163 pos macrophages and poor prognosis [103] . In parallel to the description of in situ TAM, circulating CD14 pos HLA-DR lo suppressive monocytes have been identified in B-cell NHL [104] and the absolute monocyte count is inversely correlated with overall survival in FL and DLBCL [105] . Overall, myeloid compartment display specific features in FL and contribute to FL pathogenesis through the release of tumor growth factors, proangiogenic molecules, and immunosuppressive mediators.
Relevance for the design of new therapies
Since interaction of FL B cells with their microenvironment is postulated to be an important mediator of drug resistance and disease relapse, targeting B-cell adhesion and/or retention within tumor niches has recently emerged as a promising therapeutic approach ( Figure 3 ). Anti-VLA-4 mAb natalizumab has been shown to overcome stroma-mediated resistance to Rituximab [76] . In addition, disrupting the CXCL12/CXCR4 axis using the CXCR4 antagonist perixafor (AMD3100) or cellpenetrating peptides targeting CXCR4 may augment the effects of anti-CD20 mAb [106, 107] . Interestingly, the Btk inhibitor PCI-32765, the PI3K inhibitor GS-1101, and Syk inhibitors do not only target BCR signaling but also impair chemokine networks and reduce CLL cell retention in protective microenvironment [108] [109] [110] . The combination of these two properties could be highly useful in FL. Lenalidomide also decreases CXCL12 production by stromal cells and alters CLL migration by targeting Rho protein activity [111, 112] . Finally, the tyrosine kinase inhibitor imatinib was demonstrated to impair xenografted lymphoma B-cell growth through a direct targeting of vascular mural cells resulting in loss of tumor vascular integrity [113] .
This innovative finding paves the way for the introduction of antiangiogenic agents in our therapeutic arsenal in FL.
Besides stromal cells, CD4 pos T-cell help is crucial for FL survival and growth and represents an interesting druggable target. Antagonist mAb to PD-1 and PD-L1
showed both a good safety profile and antitumor activity in some metastatic cancers [114] . They are supposed to block inhibitory PD-1 signaling on tumor infiltrating T cells or to deplete PD-1 pos anergic T cells depending on antibody isotype. In FL, PD-1 is not only expressed on anergic T cells but also on fully functional T FH and T FR , and PD-L1/PD-1 pathway has been recently demonstrated to inhibit proliferation and function of both cell types [115, 116] . The use of anti-PD-1 mAb in this specific context should thus be highly valuable but would also benefit from extensive patient monitoring to unravel the exact target of these drugs. Of course, the recent development of other immune-checkpoint inhibitors, such as anti-CTLA4 mAb should also be considered for patients with FL.
Beyond stimulation of effector immune cells, inhibition of protumoral T and stromal cells through kinase inhibitors or antagonistic mAb emerges as a valuable therapeutic approach in FL.
Malignant B cells can subvert their microenvironment
It is now well-established that tumor cells could subvert their molecular and cellular environment to favor their own growth, and to minimize anti-tumor immune response.
Accordingly, the recruitment and polarization of the various microenvironment cell subsets in FL is at least partly governed by the malignant clone (Figures 1 & 4) . CD70 and CD28-CD80/CD86 axes are involved in this process [117, 118] . Moreover, induction of TIM-3 on anergic T cells relies on malignant B-cell-derived IL-12 [26] whereas expression of multiple inhibitory ligands on B cells has been proposed to trigger T-cell synapse defect [119] . Despite data suggesting a thymic origin of mice 
